Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

ClinicalTrials.gov ID: NCT00826280

Public ClinicalTrials.gov record NCT00826280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI

Study identification

NCT ID: NCT00826280
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 347 participants

Conditions and interventions

Conditions

Coronary Artery Disease (CAD)

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 24, 2009 (Actual)
Primary completion: Jul 15, 2010 (Actual)
Completion: Jul 15, 2010 (Actual)
Last update posted: Dec 3, 2024

2009 – 2010

United States locations

U.S. sites: 25
U.S. states: 15
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Huntsville	Alabama	35801	—
Not listed	La Mesa	California	91942	—
Not listed	Mission Viejo	California	92691	—
Not listed	Roseville	California	95661	—
Not listed	Sacramento	California	95819	—
Not listed	Santa Rosa	California	95405	—
Not listed	Hartford	Connecticut	06102-5037	—
Not listed	Newark	Delaware	19173	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Miami	Florida	33173	—
Not listed	Tamarac	Florida	33321	—
Not listed	Aurora	Illinois	60504	—
Not listed	Overland Park	Kansas	66209	—
Not listed	Auburn	Maine	04210	—
Not listed	Pittsfield	Massachusetts	01201	—
Not listed	Detroit	Michigan	48202	—
Not listed	Ypsilanti	Michigan	48197	—
Not listed	Kansas City	Missouri	64111	—
Not listed	Albany	New York	12205	—
Not listed	Rochester	New York	14642-8679	—
Not listed	Columbus	Ohio	43214	—
Not listed	Philadelphia	Pennsylvania	19102	—
Not listed	Wyomissing	Pennsylvania	19610	—
Not listed	Knoxville	Tennessee	37920	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00826280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 3, 2024 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00826280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →